Patritumab
Information
- Drug Name
- Patritumab
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | NRG1 EXPRESSION NRG1 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26137564 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In this phase-2 study, 215 patients were randomize... | NRG1 | NRG1 EXPRESSION NRG1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01957280 | Completed | Phase 1 | Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287) | June 2013 | April 2014 |
| NCT02350712 | Completed | Phase 1 | Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | December 2014 | June 2016 |
| NCT02134015 | Terminated | Phase 3 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | March 2014 | November 11, 2016 |
| NCT02633800 | Terminated | Phase 2 | Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) | December 22, 2015 | February 21, 2018 |